論文 - 松浦　基樹

当科におけるASC-US症例の臨床像

竹浪 奈穂子, 松浦 基樹, 玉手 雅人, 谷垣 衣理, 早川 修

北日本産科婦人科学会総会・学術講演会プログラム・抄録集 ( 東北連合産科婦人科学会・北日本産科婦人科学会 )  60回   98 - 98  2012年09月

Evaluation of cervical conization as a definitive treatment for microinvasive cervical carcinoma and cervical intraepithelial neoplasia grade 3

Noriko Takeda, Takahiro Suzuki, Miwa Suzuki, Motoki Matsuura, Ryoichi Tanaka, Miho Fujii, Eiki Ito, Tsuyoshi Saito

ARCHIVES OF GYNECOLOGY AND OBSTETRICS ( SPRINGER HEIDELBERG )  285 ( 2 ) 453 - 457  2012年02月  [査読有り]

　概要を見る

The aim of the study was to evaluate disease persistence after conization of CIN3 and microinvasive cervical carcinoma. Medical records from a total of 231 patients were reviewed. The prevalence of CIN3 and cervical carcinoma diagnosed by means of conization were analyzed. All conizations were performed under lumbar anesthesia using a laser technique. Of the 231 patients, 25 had margin involvement with CIN3 or microinvasive carcinoma. Among these 25 patients, 10 underwent hysterectomy. Two of these 10 patients had CIN3 and eight had microinvasive carcinoma. Residual disease was observed in hysterectomy specimens from 9 of the 10 patients. Of the eight patients diagnosed with microinvasion from post-cone hysterectomy specimens, four had CIN3 and three had microinvasive carcinoma. The three patients with microinvasion were found to have a larger area of residual disease as compared with other patients with margin involvement. Conization alone seems to be a reasonable treatment for patients with CIN1, 2, 3, and microinvasive carcinoma. For adenocarcinoma, in situ treatment with conization alone is possible but requires careful follow-up. Hysterectomy appears to be a safe treatment option for microinvasive adenocarcinoma, although follow-up by cytology is sometimes possible in cases with negative surgical margins.

DOI PubMed

Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma

Motoki Matsuura, Takahiro Suzuki, Miwa Suzuki, Ryoichi Tanaka, Eiki Ito, Tsuyoshi Saito

ONCOLOGY REPORTS ( SPANDIDOS PUBL LTD )  25 ( 1 ) 41 - 47  2011年01月  [査読有り]

　概要を見る

Poor prognosis in ovarian clear cell carcinoma is associated with the expression of a defined set of proteins including osteopontin (OPN) and integrin. Statins, a family of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors, are currently being investigated for the treatment and prevention of cancer. In this study, we investigated the effects of simvastatin on ovarian clear cell carcinoma (OCCC) cells in vitro and in vivo and elucidated the mechanism of drug action. Changes in OPN gene expression were determined by real-time RT-PCR, and an MTT assay was performed to determine effects on cell proliferation. Finally, a xenograft tumor model was constructed to evaluate the effects of simvastatin on cell proliferation and apoptosis in vivo. According to our experimental results. OPN is an important protein in OCCC. Simvastatin inhibited OCCC cell proliferation, and the inhibition rate was approximately 40% to 50% after treatment with 10 mu M simvastatin for 48 h. In the xenograft studies, simvastatin treatment resulted in a significant growth inhibition. Furthermore, the mice treated with simvastatin survived significantly longer compared to the control groups. In conclusion, simvastatin has anticancer effects in vitro and in vivo. Further confirmation of the anticancer effects of statins in future studies will increase the scope for OCCC treatment.

DOI PubMed

Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy

Motoki Matsuura, Takahiro Suzuki, Tsuyoshi Saito

CANCER SCIENCE ( WILEY-BLACKWELL )  101 ( 8 ) 1828 - 1833  2010年08月  [査読有り]

　概要を見る

Recent studies have demonstrated overexpression of osteopontin (OPN) in ovarian clear cell carcinoma. Here, we revealed the role of OPN in invasiveness in ovarian clear cell carcinoma. We used immunofluorescence analysis to detect OPN in a total of 160 patient-derived specimens. Ovarian clear cell carcinoma cell lines, RMG-1 and TOV-21G, were used to monitor changes in OPN and integrin levels, and cell invasiveness following treatment with OPN, simvastatin, and transfection with siRNA. Immunofluorescence analysis revealed statistically significant differences among the histological groups, and ovarian clear cell carcinoma expressed a strong OPN signal. The OPN receptors, alpha v and 5, and beta 1 and 3 integrins, were increased after treatment with OPN. Invasion assays indicated that OPN enhanced in vitro extracellular matrix invasion dose-dependently in ovarian clear cell carcinoma. Simvastatin significantly reduced expression of OPN and the integrins, and decreased ECM invasion. RNA interference also suppressed ECM invasion. These results suggest that down- or up-regulation of OPN is involved in carcinoma cell invasion. We thus conclude that OPN regulation could have a crucial role in ovarian clear cell carcinoma therapy. (Cancer Sci 2010).

DOI PubMed

Prediction of Histologic Type and Lymph Node Metastasis for Advanced Ovarian Cancer on Uterine Cervical and Endometrial Cytology

Miwa Suzuki, Takahiro Suzuki, Motoki Matsuura, Masahiro Iwasaki, Ryoichi Tanaka, Eiki Ito, Miho Fujii, Tsuyoshi Saito

ACTA CYTOLOGICA ( SCI PRINTERS & PUBL INC )  54 ( 4 ) 575 - 581  2010年07月  [査読有り]

　概要を見る

Objective To evaluate usefulness of uterine cervical and endometrial cytology for detecting ovarian cancer and predicting histologic type. Study Design Retrospective analysis was performed on uterine cervical and endometrial cytology data on 163 patients with ovarian cancer. Results Cervical and endometrial abnormalities were detected in 10 and 19 of the patients evaluated. Patients whose cervical and endometrial cytology revealed abnormal cells were classified as having ovarian cancer at International Federation of Gynecology and Obstetrics (FIGO) stages ill and IV Peritoneal cytology proved positive in many of the patients with abnormal findings on uterine cytologic analysis. Of the 19 patients with positive uterine cytologic findings, 12 had recurrence tases were detected in 9 of 19 patients. Our findings indicated that it is possible to predict histologic type in ovarian cancer in 90% of cases of positive cervical smears and 79% of abnormal endometrial smears. Conclusion Our study showed that most of the ovarian cancer cases that had abnormalities in uterine cervical and endometrial cytologic tests exhibited progression of disease. As a consequence, Our findings indicate that it is possible to predict development of ovarian cancer and its histologic type using cytology screening. (Acta Cytol 2010;54:575-581)

DOI PubMed

Successful Uterus-Preserving Surgery for Treatment of Chemotherapy-Resistant Placenta Increta

Toshiaki Endo, Takuhiro Hayashi, Ayumi Shimizu, Motoki Matsuura, Masahito Mizuuchi, Kunihiko Nagasawa, Yoshiaki Ezaka, Tuyoshi Baba, Shinichi Ishioka, Tsuyoshi Saito

GYNECOLOGIC AND OBSTETRIC INVESTIGATION ( KARGER )  69 ( 2 ) 112 - 115  2010年  [査読有り]

　概要を見る

Treatment of placenta increta often entails abdominal total hysterectomy. We present a case of placenta increta in which 3-dimensional computed tomography shows very high blood flow to the placenta, even after chemotherapy with methotrexate. Nonetheless, we were able to remove the region of the uterus that had been invaded by chorionic villi. Massive bleeding during the operation was prevented by ligation of the hypogastric artery and local injection of vasopressin. The combination of chemotherapy and partial resection of the uterus is quite a unique treatment for placenta increta patients. This approach enabled preservation of the uterus and the patient's fertility. We suggest this procedure could be one of the treatments for patients who have placenta increta and wish to retain their fertility. Copyright (C) 2009 S. Karger AG, Basel

DOI PubMed

Chemotherapy (CT) with radiotherapy versus CT alone for FIGO Stage IIIc endometrial cancer

M. Matsuura, T. Suzuki, M. Morishita, R. Tanaka, E. Ito, T. Saito

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY ( I R O G CANADA, INC )  30 ( 1 ) 40 - 44  2009年  [査読有り]

　概要を見る

To determine optimal treatment for women with Stage IIIc endometrial carcinoma, extended-field radiotherapy (RT) plus chemotherapy (CT) was compared versus CT alone as adjuvant therapy. Twenty-nine patient's with FIGO Stage IIIc endometrial cancer who underwent adjuvant treatment with 4.4 courses of CT (CAP or TC/DC) or 4.5 Courses of CT (CAP or TC/DC) plus external pelvic RT (50 Gy) with paraaortic boost after surgery between 1992 and 2004 were retrospectively assessed. Fifteen patients underwent CT alone and 14 received combined treatment with CT/RT. Following treatment, the recurrence rate was 46.6% and 28.5% in the two treatment arms. respectively. There was a significant (p < 0.05) difference in the pelvic recurrence rate (33.3% and 7.1%, respectively). Combined treatment with RT/CT was associated with a better survival rate than CT alone (78% versus 62%, respectively). In Stage IIIc endometrial cancer, combined treatment with RT and CT reduces pelvic recurrence and improves progression-free survival and overall Survival compared with CT alone.

PubMed

Analgesic Efficacy of Controlled-release Oxycodone in Patients With Uterine or Ovarian Cancer

Takahiro Suzuki, Miyuki Morishita, Eiki Ito, Motoki Matsuura, Ryoichi Tanaka, Tsuyoshi Saito

AMERICAN JOURNAL OF THERAPEUTICS ( LIPPINCOTT WILLIAMS & WILKINS )  15 ( 1 ) 31 - 35  2008年01月  [査読有り]

　概要を見る

Treatment with opioid analgesics often causes adverse reactions that may make continuous use of such drugs difficult. We investigated the efficacy and safety of controlled-release oxycodone in the treatment of gynecologic cancer pain. The patients included 14 with cervical cancer, 6 with corpus cancer, and 17 with ovarian cancer. Treatment with controlled-release oxycodone was started at 5 mg/dose when pain control using nonsteroidal anti-inflammatory drugs became ineffective. The dose was titrated to the optimal level over a mean duration of 2.34 +/- 1.13 days, and the initially optimal dose was 18.92 +/- 5.23 mg/day. Although no patients experienced confusion, vomiting, or respiratory depression, 17 patients experienced adverse events, including constipation in 14 patients and nausea in 9 patients. The incidence of nausea was low in patients receiving oxycodone and prochlorperazine. In the present study, patients with moderate to severe pain caused by gynecologic cancer could successfully be treated with controlled-release oxycodone.

DOI PubMed